The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance
Journal of Cell Biology · 2023
DOI: 10.1083/jcb.202212072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Biology, 2023. Verfasst von Shan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, Colle…. Hauptthemen laut MEDLINE: Neoplasms, Ubiquitin-Protein Ligases, Endopeptidases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Key Program for International S&T Cooperation Projects of China.
Abstract (Originalsprache)
The dependency of cancer cells on iron increases their susceptibility to ferroptosis, thus providing new opportunities for patients with treatment-resistant tumors. However, we show that lipid peroxidation, a hallmark of ferroptosis, was found in various areas of patient samples, indicating the potential resistance of ferroptosis. Using whole deubiquitinases (DUBs) sgRNA screening, we found that loss of ZRANB1 confers cancer cell resistance to ferroptosis. Intriguingly, functional studies revealed that ZRANB1 ubiquitinates and represses SLC7A11 expression as an E3 ubiquitin ligase and that ZRANB1 inhibits glutathione (GSH) synthesis through SLC7A11 degradation, leading to elevated lipid peroxidation and ferroptosis. Deletion of the region (residues 463–584) abolishes the E3 activity of ZRANB1. Moreover, we show that ZRANB1 has lower expression in tumors, which is positively correlated with lipid peroxidation. Collectively, our results demonstrate the role of ZRANB1 in ferroptosis resistance and unveil mechanisms involving modulation of E3 ligase activity through an unconventional catalytic domain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Tongji Hospital, Huazhong Universit…
- Translational Medicine Center, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine , Shanghai, China.
- Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College , Nanchang, China.
- Department of Biochemistry and Molecular Biology, The Institute of Molecular and Translational Medicine, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Shan Huang, Qimin Zhang, Manyu Zhao, Xing Wang, Yilei Zhang, Boyi Gan, Peijing Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Key Program for International S&T Cooperation Projects of China
- Huazhong University of Science and Technology
- National Young Talents Program of China
Zitieren
APA
Huang, S., Zhang, Q., Zhao, M., Wang, X., Zhang, Y., Gan, B., & Zhang, P. (2023). The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance. Journal of Cell Biology. https://doi.org/10.1083/jcb.202212072
Vancouver
Huang S, Zhang Q, Zhao M, Wang X, Zhang Y, Gan B, et al. The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance. Journal of Cell Biology. 2023. doi:10.1083/jcb.202212072
BibTeX
@article{Huang2023,
author = {Huang, Shan and Zhang, Qimin and Zhao, Manyu and Wang, Xing and Zhang, Yilei and Gan, Boyi and Zhang, Peijing},
title = {The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance},
journal = {Journal of Cell Biology},
year = {2023},
doi = {10.1083/jcb.202212072}
}
EUVIMED